AAV Capsid Peptide Insertions for Tissue-Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant adeno-associated viruses (rAAVs) face limitations in efficiently transducing certain cell types and selectively targeting specific tissues or organs after systemic delivery, constraining their effectiveness in gene therapy and scientific studies.
Innovation Solution
Development of AAV vectors with specific peptide sequences, such as QAVRTSL and 11 contiguous amino acid sequences, that are integrated into the capsid protein to enhance targeting and transduction efficiency to specific tissues like the central nervous system, peripheral nervous system, and heart.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional AAV capsids are used for systemic delivery, then broad distribution is achieved, but selective targeting of specific tissues or organs is insufficient
Solution Approach 1:
The patent applies local quality by inserting specific peptide sequences (such as QAVRTSL and 11 contiguous amino acid sequences) at targeted locations within the AAV capsid protein structure. These localized peptide modifications confer specific tissue targeting properties to particular regions of the capsid, enabling selective binding to receptors on target cells in the central nervous system, peripheral nervous system, and heart while maintaining overall capsid functionality.
Solution Approach 2:
The patent employs parameter changes by systematically varying the amino acid sequences inserted into the capsid protein at different positions and configurations. By changing the peptide sequence parameters (comparing QAVRTSL versus 11 amino acid sequences, and their different insertion locations), the invention optimizes the balance between systemic delivery capability and specific tissue targeting efficiency, achieving enhanced transduction of target cells.
2Productivity
If AAV vectors are modified with targeting peptides, then transduction efficiency to specific cell types improves, but capsid protein complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the capsid modification into discrete, modular peptide insertions rather than comprehensive restructuring. Specific short peptide sequences (7-11 amino acids) are inserted at defined locations within the capsid protein, allowing the majority of the native capsid structure to remain unchanged and functional while adding targeted functionality in localized segments.
Solution Approach 2:
The patent employs composite materials by creating hybrid capsid structures that combine the native AAV capsid protein with exogenously inserted peptide sequences. This composite approach merges the advantageous properties of the original capsid (stability, packaging capability) with the targeting functionality of the inserted peptides, achieving enhanced transduction efficiency without completely redesigning the capsid architecture.
Data Source
AI summary
Disclosed herein are peptide sequences capable of directing adeno-associated viruses (AAV) to target specific environments, for example the nervous system and the heart, in a subject. Also disclosed are AAVs having non-naturally occurring capsid proteins comprising the disclosed peptide sequences, and methods of using the AAVs to treat diseases.